ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
ZZ-IT-ICI-HCC 1line-023
Phase 2 small_molecule active
Quick answer
ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab for Liver Cancer is a Phase 2 program (small_molecule) at Second Affiliated Hospital of Soochow University with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Second Affiliated Hospital of Soochow University
- Indication
- Liver Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active